New England Journal of Medicine· 2017Q1· Clinical trial

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation

Richard M. Stone, Sumithra J. Mandrekar, Ben L. Sanford, Kristina Laumann et al.

2,209citations
Q1SCImago
2017year

Short summary

Adding the kinase inhibitor midostaurin to standard chemotherapy significantly improved overall survival for patients with acute myeloid leukemia (AML) and a FLT3 mutation.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Hematology

HematologyMedicine